Zoledronic acid monotherapy as an effective treatment for lung adenocarcinoma and bone metastasis: A case report
Hiroyuki Shimadaa Yukihisa Inouea, b Tetsu Haraa Naoki Kawakamia, c Shuta Yamauchia Yasuto Jina
aDivision of Respiratory Medicine, Hiratsuka Kyosai Hospital
bDepartment of Respiratory Medicine, Tokyo Medical and Dental University
cDepartment of Respiratory Medicine, Tsuchiura Kyodo Hospital
We present here the case of a 72-year-old man with lung adenocarcinoma in the left upper lobe and bone metastasis in the left ninth rib. Chemotherapy was stopped because of drug resistance, and only palliative treatment was continued. Simultaneously, denosumab was replaced with zoledronic acid. The primary tumor and the bone lesion shrank significantly; the diameter of the primary lesion decreased from 81 mm to 41 mm, and the patient felt no more pain. Zoledronic acid has now been administered for 21 months. The rare course observed in this case results from the potent antitumor effect of zoledronic acid.
Zoledronic acid Antitumor effect Lung cancer Bone metastasis Gamma delta T cells
Received 22 Jun 2015 / Accepted 19 Sep 2015
AJRS, 5(1): 8-12, 2016